| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | tafluprost (Saflutan®) |
| Formulation | 15 micrograms/ml eye drops |
| Reference number | 4347 |
| Indication | Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension: as monotherapy in patients who would benefit from preservative-free eye drops, are insufficiently responsive to first line therapy, or intolerant or contraindicated to first line therapy; as adjunctive therapy to beta-blockers |
| Company | Santen UK Ltd |
| BNF chapter | Eye |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 22/07/2019 |